dna-istock-518143098-ralwel--2
ralwel / iStockphoto.com
13 July 2018BiotechJakob Wested, Timo Minssen, Esther van Zimmeren

Will the EPO’s Enlarged Board hear the Broad’s CRISPR case?

“The Opposition Division’s interpretation of the European Patent Convention (EPC) is inconsistent with treaties designed to harmonise the international patent process, including that of the US and Europe.” This was the rather strong reaction of the Broad Institute (BI) after the European Patent Office’s (EPO) Opposition Division’s (OD) decision to revoke one of its CRISPR patents.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotech
21 July 2026   Now a Danaher subsidiary, the company is contesting a number of orders after a California court finalised several aspects of the high-profile dispute.
Biotech
20 July 2026   The biotech company has launched a trio of lawsuits against two vaccine makers, while announcing receipt of a $178 million sum from Moderna under a previous deal.
Biotech
16 July 2026   A Munich court ruled that Illumina infringed a rival’s DNA sequencing patents, handing the challenger an early victory in a dispute that is playing out across Europe and the US.